Semaglutide
Research highlights
- ✓Well-characterised GLP-1 receptor agonist with extensive research literature
- ✓May support appetite, blood-glucose and cardiovascular outcome research
- ✓Ideal reference compound for GLP-1 comparison studies
- ✓Outstanding value — most accessible GLP-1 compound in our range
Read Carl's plain-English guide: Semaglutide on Peptide Carl ›
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that became one of the most widely studied compounds in metabolic medicine. Its extensive literature makes it an excellent research benchmark.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
How do I order?
Click the WhatsApp button, message us your order, and we'll confirm details and ship to you quickly.
Semaglutide, explained
The short version: Semaglutide is the GLP-1 drug behind Novo Nordisk's Ozempic and Wegovy. It is the most heavily tested compound in this category, with a heart outcomes trial of more than 17,000 people behind it.
What it is
Semaglutide is an engineered version of GLP-1, a hormone released by the gut that acts on appetite. It acts on one receptor only, the GLP-1 receptor. Tirzepatide adds a second (GIP) and retatrutide a third (glucagon), so semaglutide is the single-receptor benchmark the newer compounds get measured against.
What the trials found
STEP 1 (New England Journal of Medicine, 2021) gave once-weekly semaglutide or placebo to 1,961 adults with obesity or overweight and no diabetes. After 68 weeks, average body weight was down 14.9% on semaglutide against 2.4% on placebo. Nausea and diarrhoea were the most common side effects, mostly mild and fading over time.
SELECT (NEJM, 2023) went after a harder question: does it change heart outcomes? It enrolled 17,604 people with existing heart disease, overweight or obesity, and no diabetes. Heart attack, stroke or cardiovascular death happened to 6.5% on semaglutide against 8.0% on placebo, roughly a 20% relative drop. The catch: 16.6% stopped the drug because of side effects, double the placebo rate.
| Brand | When | Approved for |
|---|---|---|
| Ozempic | Dec 2017 | Blood sugar control in adults with type 2 diabetes |
| Wegovy | 2021 | Chronic weight management |
| Wegovy | Mar 2024 | Cutting the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight |
| Wegovy | Aug 2025 | MASH liver disease with moderate to advanced scarring (accelerated approval) |
Where the evidence stops
All of that comes from Novo Nordisk's own pharmaceutical product. Wegovy's prescribing information carries a boxed warning about the risk of thyroid C-cell tumours. The FDA also points out that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, and it had logged 990 adverse event reports linked to compounded semaglutide by May 2026, some involving hospital stays after dosing mistakes. Research-grade material is not Wegovy, and the trial numbers do not transfer to it.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
The one-receptor original with the deepest evidence base in the field, all of it earned by the branded drug, not research powder.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Semaglutide
No reviews from orders with Semaglutide yet. Here is what recent customers said about ordering from us.
★★★★★
Great service as always
Nico V. · 6 Oct 2026
★★★★★
I am happy with my product
Kholofelo L. · 30 Sep 2026
★★★★
Small checkout glitch, but after following up it was quickly sorted out and everything went smoothly from there. Good customer service - thank you.
Tonia K. · 30 Sep 2026
★ 4.8 across all 16 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
+ GH-Axis entry — CJC-1295 + Ipamorelin
The same pairing in a single vial. Half the total peptide of the full stack below, and the cheaper way in.
+ Glutathione
The compound most often researched alongside a metabolic protocol.
+ AOD-9604
Filed in the same research area as the compound you are viewing.
+ GH-Axis — CJC-1295 + Ipamorelin
The GHRH + GHRP pairing most commonly researched alongside a GLP-1 protocol.
+ MOTS-c
A mitochondrial-derived peptide commonly researched alongside GLP-1 protocols.
+ Tesamorelin
A GHRH analogue often researched in GLP-1 body-composition work.
+ GHK-Cu
A copper peptide researched for skin & tissue alongside GLP-1 protocols.
+ NAD+
A cellular-energy & longevity-research staple paired with GLP-1 protocols.
